The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|March 2, 2017
- Pharmaceutical Technology-03-02-2017
- Volume 41
- Issue 3
Tabletop Pill Counter Automatically Counts and Fills Solid Oral-Dose Products
The Pharmafill TC4 Tabletop electronic tablet counter from Deitz Co. automatically counts pills, tablets, capsules, softgels, caplets, lozenges, and other solid oral-dose products and fills them into bottles.
The Pharmafill TC4 Tabletop electronic tablet counter from Deitz Co. automatically counts pills, tablets, capsules, softgels, caplets, lozenges, and other solid oral-dose products and fills them into bottles. The Pharmafill TC4 counts translucent, transparent, and opaque solid oral-dose products at up to 2000 per minute. The Tabletop TC4 is a computer-controlled operation, and measures 34 inches across, 21 inches deep, and 30 inches in height. The TC4 entry level counter includes an air guide system that automatically separates and aligns the pills on a single layer, a vibratory hopper feeder that automatically regulates the flow of tablets into the counter, and an optional smart bottle sensing system that automatically stops operation in the event of a problem with the bottle.
Articles in this issue
over 9 years ago
Understanding Containmentover 9 years ago
International Trade Issues Threaten Global Pharma Operationsover 9 years ago
Oral Delivery of Biologic APIs: The Challenge Continuesover 9 years ago
Covering Global Regulations in a Quality Systemover 9 years ago
Risk-Based Predictive Stability–An Industry Perspectiveover 9 years ago
Quality Agreements:Managing Global Relationshipsover 9 years ago
Achieving Manufacturing Excellenceover 9 years ago
Loading Bench for Cold-Chain Managementover 9 years ago
Mixers for Blending ApplicationsRelated to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.